Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early operable breast cancer.

A C Wolff1, N E Davidson

  • 1The Johns Hopkins Oncology Center, Cancer Research Building, Room 189, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026
Same author

Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

HER2DX genomic test in early-stage HER2-positive breast cancer.

ESMO open·2024

For early operable breast cancer, breast conservation therapy (BCT) is preferred. While systemic therapies reduce recurrence risk, primary systemic therapy (PST) doesn't improve survival over adjuvant treatments.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Early operable breast cancer presents a risk of systemic recurrence and death despite potential curability.
  • Breast conservation therapy (BCT) is the recommended surgical approach for most early operable breast cancer patients.
  • Adjuvant systemic therapies offer risk reduction but do not eliminate recurrence and mortality.

Purpose of the Study:

  • To evaluate the efficacy of neoadjuvant or primary systemic therapy (PST) in operable breast cancer.
  • To assess the survival advantage of PST compared to standard adjuvant approaches.
  • To review current findings on high-dose chemotherapy and adjuvant radiation therapy in high-risk early breast cancer.

Main Methods:

  • Review of current treatment strategies for early operable breast cancer.

Related Experiment Videos

  • Analysis of outcomes for patients receiving PST versus adjuvant systemic therapy.
  • Examination of early results from high-dose chemotherapy trials.
  • Assessment of the role of adjuvant radiation therapy post-mastectomy.

    • Main Results:

    • Primary systemic therapy (PST) slightly increases breast conservation rates but does not provide a survival advantage over adjuvant therapy.
    • PST can identify patients with a better prognosis (pathologic complete response).
    • High-dose chemotherapy has not shown an advantage over conventional doses in high-risk patients.
    • The necessity of adjuvant radiation therapy after mastectomy for high-risk cases remains undefined.

    Conclusions:

    • Breast conservation therapy (BCT) is the preferred surgical option for early operable breast cancer.
    • Current primary systemic therapy (PST) strategies do not offer a survival benefit over adjuvant treatments.
    • Further research is needed to define the role of adjuvant radiation therapy in high-risk early breast cancer.